Simple Saliva Test May Detect Early Cancer

Publication
Article
OncologyONCOLOGY Vol 12 No 8
Volume 12
Issue 8

An ideal diagnostic test for cancer would be noninvasive and provide accurate results with sufficient specificity and sensitivity. Currently, no test for cancer meets all of these criteria. However, results of a study presented at the annual meeting of the

An ideal diagnostic test for cancer would be noninvasive and provide accurate results with sufficient specificity and sensitivity. Currently, no test for cancer meets all of these criteria. However, results of a study presented at the annual meeting of the American Association for Cancer Research (AACR) raise hope that a noninvasive, accurate way to detect certain types of cancer with a simple saliva test may soon be available.

Markers Specific to Squamous Cell Carcinoma

David Sidransky, md, professor and director of the Head and Neck Cancer Research Division, Andre L. Reed, MD, and Michael F. Spafford, MD, head and neck oncology fellow and instructor, respectively, at Johns Hopkins University School of Medicine, and colleagues have developed a test that uses saliva to detect squamous cell cancer of the head and neck.

Using molecular analysis, the investigators compared the saliva of 21 patients undergoing surgery for head and neck squamous cell carcinoma with cells from the actual tumors. They found certain markers in saliva specific to the tumor type in 71% of the cancer patients. By contrast, saliva from 27 tumor-free controls--smokers and nonsmokers without tumors--failed to show any of the specific markers.

"While a positive result seems to be specific to squamous cell carcinoma of the head and neck, the test is not yet able to detect all patients with this type of cancer," said Dr. Spafford. "We are currently working on improving the detection rate of the test, optimizing the collection method, and analyzing the saliva of tumor patients following treatment. Early detection would allow us to treat these patients less invasively, thus sparing them from the potentially disfiguring and disabling effects of surgery."

Related Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
head and neck cancer